Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|August 23, 2013
[The electronic health record: computerised provider order entry and the electronic instruction document as new functionalities]Joep P M Derikx, Frans L G Erdkamp, A G M Hoofwijk
Critical Reviews in Oncology/Hematology|June 30, 2020
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practiceAnouk K M Claessens, Khava I E Ibragimova, Sandra M E Geurts, et al.
Breast Cancer Research and Treatment|November 30, 2019
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancerAnouk K M Claessens, Reinier Timman, Jan J Busschbach, et al.
Acta Oncologica (Stockholm, Sweden)|March 7, 2020
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancerAnouk K M Claessens, Frans L G Erdkamp, Marta Lopez-Yurda, et al.
BMC Medicine|June 9, 2018
Four-year effects of exercise on fatigue and physical activity in patients with cancerLenja Witlox, Anouk E Hiensch, Miranda J Velthuis, et al.
International Journal of Cancer|August 30, 2021
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE RegistryMarissa Meegdes, Sandra M E Geurts, Frans L G Erdkamp, et al.
BMC Cancer|August 19, 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRuben T H M Larue, Lien Van De Voorde, Maaike Berbée, et al.
Breast Cancer Research and Treatment|August 20, 2018
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)Anouk K M Claessens, Monique E M M Bos, Marta Lopez-Yurda, et al.
Eclinicalmedicine|March 30, 2023
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialVivianne C G Tjan-Heijnen, Senna W M Lammers, Sandra M E Geurts, et al.
Cancer|June 18, 2016
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trialJan C Drooger, Harm van Tinteren, Steffen M de Groot, et al.
Pageof 3